Compare Manchester United PLC (MANU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Recursion Pharmaceuticals Inc — how do they compare? Manchester United PLC trades at $22.23 (market cap $3.80B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Manchester United PLC is far larger — about 2.1× Recursion Pharmaceuticals Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MANU | RXRX | |
|---|---|---|
Market Cap | $3.80B | $1.81B |
Sector | Media | Health |
52-Week High | $23.53 | $6.79 |
52-Week Low | $15.10 | $2.84 |
Enterprise Value | $4.74B | $1.33B |
Dividend Yield | 1.26% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
